Utilize este identificador para referenciar este registo: https://hdl.handle.net/10316/92845
Título: Development of levofloxacin-loaded PLGA microspheres of suitable properties for sustained pulmonary release
Autor: Gaspar, Marisa C. 
Pais, Alberto A. C. C. 
Sousa, João J. S. 
Brillaut, Julien
Olivier, Jean-Christophe
Palavras-chave: Cystic Fibrosis; lung delivery; Levofloxacin-loaded PLGA MS; Physico-chemical characterization; Controlled release; In vitro studies
Data: 2019
Editora: Elsevier
Projeto: SFRH/BD/80307/2011 
Título da revista, periódico, livro ou evento: International Journal of Pharmaceutics
Volume: 556
Resumo: Aerosol antibiotics are an interesting alternative to oral or intravenous therapy in Cystic Fibrosis lung infections. Levofloxacin (LVX) inhaled solution is already an effective option. In this study, the aim was the development of LVX-loaded PLGA microspheres (MS) for pulmonary administration as a dry powder. MS were prepared, for the first time, by a modified double emulsion solvent evaporation method with premix membrane homogenization. Aqueous phases were saturated with LVX and a fatty acid (lauric acid) was added to avoid the drug escaping from the organic phase. MS were characterized in terms of size, drug content, morphology and in vitro release properties. X-ray diffraction, Fourier-transform infrared spectroscopy, differential and gravimetric thermal analysis, and cytotoxicity analyses were performed. Results showed this new method increased the drug loading while maintaining an adequate (∼5 µm) particle size and controlled release. Compared to a solution for inhalation, these properties combined with the dry-powder nature of these MS will improve patient compliance. The incorporation of lauric acid was not advantageous because the particle size was higher and no improvements concerning the sustained release occurred. LVX was molecularly dispersed in the matrix, or it was in amorphous state, as confirmed by the physico-chemical analyses. Calu-3 cell viability assays demonstrated no cytotoxicity for these MS, making them a promising system for LVX pulmonary delivery.
URI: https://hdl.handle.net/10316/92845
ISSN: 0378-5173
DOI: 10.1016/j.ijpharm.2018.12.005
Direitos: embargoedAccess
Aparece nas coleções:FFUC- Artigos em Revistas Internacionais

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato
Gaspar et al 2018.pdf2.62 MBAdobe PDFVer/Abrir
Mostrar registo em formato completo

Google ScholarTM

Verificar

Altmetric

Altmetric


Este registo está protegido por Licença Creative Commons Creative Commons